No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial
Background Untreated HIV may increase the risk of cardiovascular events . Our preliminary in vitro and in vivo research suggests that pentoxifylline ( PTX ) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy . Methods We performed a r and omized , placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants . The primary endpoint was change in flow-mediated dilation ( FMD ) of the brachial artery after 8 weeks . Nitroglycerin-mediated dilation ( NTGMD ) and circulating markers of inflammation , cellular immune activation , coagulation , and metabolism were also assessed . Results The difference in mean absolute change ( SD ) in FMD after 8 weeks between the placebo [ −1.06 (1.45)% ] and PTX [ −1.93 (3.03)% ] groups was not significant ( P = 0.44 ) . No differences in NTGMD were observed . The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 ( sTNFRI ) [ −83.2 pg/mL in the placebo group vs. + 65.9 pg/mL in the PTX group ; P = 0.03 ] . PTX was generally well-tolerated . Conclusions PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy . Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population . Trial Registration Clinical Trials.gov
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .